Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo.

Yin, Yuzhen; Zhang, Pengchao; He, Ling; Guo, Xianling; Wang, Hui; Li, Jun; Xu, Qing

Yin, Yuzhen; Zhang, Pengchao; He, Ling; Guo, Xianling; Wang, Hui; Li, Jun; Xu, Qing.

Afiliación

Yin Y; Department of Oncology, The Affiliated Shanghai No. 10 People's Hospital, Nanjing Medical University, Shanghai 200072, China.
Zhang P; Department of Tumor Center, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou 215228, China.
He L; Fundamenta Therapeutice Co. Ltd, Suzhou 215200, China.
Guo X; Fundamenta Therapeutice Co. Ltd, Suzhou 215200, China.
Wang H; Department of Oncology, The Affiliated Shanghai No. 10 People's Hospital, Nanjing Medical University, Shanghai 200072, China.
Li J; Department of Oncology, The Affiliated Shanghai No. 10 People's Hospital, Nanjing Medical University, Shanghai 200072, China.
Xu Q; Fundamenta Therapeutice Co. Ltd, Suzhou 215200, China.

Evid Based Complement Alternat Med ; 2022: 1227308, 2022.

Article en En | MEDLINE | ID: mdl-36034960

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Evid Based Complement Alternat Med Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google